Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Saratoga Research & Investment Management

Saratoga Research & Investment Management raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,549,469 shares of the company’s stock after acquiring an additional 39,123 shares during the quarter. Novo Nordisk A/S comprises approximately 5.0% of Saratoga Research & Investment Management’s holdings, making the stock its 7th largest position. Saratoga Research & Investment Management owned about 0.06% of Novo Nordisk A/S worth $79,085,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVO. Tdam USA Inc. lifted its stake in shares of Novo Nordisk A/S by 1.5% in the first quarter. Tdam USA Inc. now owns 14,766 shares of the company’s stock worth $772,000 after buying an additional 214 shares during the last quarter. EagleClaw Capital Managment LLC lifted its stake in shares of Novo Nordisk A/S by 0.6% in the first quarter. EagleClaw Capital Managment LLC now owns 40,499 shares of the company’s stock worth $2,122,000 after buying an additional 225 shares during the last quarter. Cardinal Capital Management lifted its stake in shares of Novo Nordisk A/S by 0.6% in the first quarter. Cardinal Capital Management now owns 41,292 shares of the company’s stock worth $2,159,000 after buying an additional 236 shares during the last quarter. Ballentine Partners LLC lifted its stake in shares of Novo Nordisk A/S by 3.5% in the first quarter. Ballentine Partners LLC now owns 7,220 shares of the company’s stock worth $378,000 after buying an additional 242 shares during the last quarter. Finally, Enterprise Financial Services Corp lifted its stake in shares of Novo Nordisk A/S by 46.4% in the first quarter. Enterprise Financial Services Corp now owns 817 shares of the company’s stock worth $42,000 after buying an additional 259 shares during the last quarter. Hedge funds and other institutional investors own 7.12% of the company’s stock.

Several research firms recently commented on NVO. Barclays upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 target price for the company in a research note on Tuesday, June 11th. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 target price for the company in a research note on Monday, July 15th. UBS Group reiterated a “buy” rating and set a $355.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, June 19th. Deutsche Bank cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 target price for the company. in a research note on Thursday, June 20th. Finally, Credit Suisse Group upgraded shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the stock. Novo Nordisk A/S has an average rating of “Hold” and an average price target of $111.58.

NYSE:NVO traded up $0.15 during trading hours on Friday, hitting $48.72. 1,285,362 shares of the company traded hands, compared to its average volume of 1,684,996. The company has a market capitalization of $117.40 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 2.20 and a beta of 0.60. Novo Nordisk A/S has a twelve month low of $41.23 and a twelve month high of $52.83. The stock’s 50-day moving average price is $49.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.96 and a quick ratio of 0.66.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Friday, May 3rd. The company reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.04. The firm had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $4.35 billion. Novo Nordisk A/S had a net margin of 33.60% and a return on equity of 78.28%. On average, analysts expect that Novo Nordisk A/S will post 2.43 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Read More: Understanding the different types of bonds

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.